Literature DB >> 7572659

Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure.

T Tsutamoto1, T Hisanaga, D Fukai, A Wada, Y Maeda, K Maeda, M Kinoshita.   

Abstract

We tested the hypothesis that plasma endothelin-1 (ET-1) and soluble intercellular adhesion molecule-1 (sICAM-1) in patients with congestive heart failure (CHF) are related to subsequent survival, and assessed whether the measurements of these substances provide additional prognostic information to that obtained from clinical and biochemical variables previously known to be associated with high mortality. Plasma levels of sICAM-1 and ET-1 were measured in 102 patients with CHF (left ventricular ejection fraction [LVEF] < 0.45), and patients were followed up for > 18 months. The plasma level of sICAM-1 increased with the severity of CHF (normal, 149 +/- 10 ng/ml, mild CHF [New York Heart Association functional class II], 207 +/- 9.4 ng/ml, severe CHF [functional class III or IV], 293 +/- 18 ng/ml). The plasma level of ET-1 also increased with the severity of CHF (normal, 1.5 +/- 0.2 pg/ml, mild CHF, 2.1 +/- 0.1 pg/ml, severe CHF, 4.0 +/- 0.4 pg/ml). Plasma levels of both sICAM-1 and ET-1 decreased after treatment in 14 patients, with improvements in symptoms (from functional class IV to II) during the follow-up period. There was a significant positive correlation between the plasma level of ET-1 and plasma sICAM-1 (r = 0.44, p < 0.001). A significant negative correlation was observed between LVEF and plasma ET-1 (r = -0.34, p < 0.001), and plasma sICAM-1 (r = -0.36, p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572659     DOI: 10.1016/s0002-9149(99)80231-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  29 in total

1.  Inflammatory mediators in chronic heart failure: an overview.

Authors:  Stefan D Anker; Stephan von Haehling
Journal:  Heart       Date:  2004-04       Impact factor: 5.994

Review 2.  Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure.

Authors:  H Krum; R Denver; A Tzanidis; P Martin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 3.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 4.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

5.  The role of the neurohormonal system in heart failure.

Authors:  M Komajda; F Pousset; R Isnard; P Lechat
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

6.  Acute effects of inhaled urban particles and ozone: lung morphology, macrophage activity, and plasma endothelin-1.

Authors:  L Bouthillier; R Vincent; P Goegan; I Y Adamson; S Bjarnason; M Stewart; J Guénette; M Potvin; P Kumarathasan
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

Review 7.  Chronic heart failure and the immune system.

Authors:  Daniela Mari; Federica Di Berardino; Massimo Cugno
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

Review 8.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 9.  Biomarkers in heart failure: a clinical review.

Authors:  J Paul Rocchiccioli; John J V McMurray; Anna F Dominiczak
Journal:  Heart Fail Rev       Date:  2008-12-03       Impact factor: 4.214

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.